Dinges, WarrenGirard, Pierre-MariePodzamczer Palter, DanielBrockmeyer, Norbert H.García, FelipeHarrer, ThomasLelievre, Jean-DanielFrank, IanColin De Verdiere, NathalieYeni, Guy-PatrickOrtega Gonzalez, EnriqueRubio, RafaelClotet, Bonaventura, 1953-DeJesus, EdwinPérez Elías, María JesúsLaunay, OdilePialoux, GillesSlim, JihadWeiss, LaurenceBouchaud, OlivierFelizarta, FrancoMeurer, AnjaRaffi, FrançoisEsser, StefanKatlama, ChristineKoletar, Susan L.Mounzer, KaramSwindells, SusanBaxter, JohnSchneider, StefanChas, JulieMolina, Jean-MichelKoutsoukos, MargueriteCollard, AlixBourguignon, PatriciaRoman, François2018-12-112018-12-112016-02https://hdl.handle.net/2445/126890The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on HIV-1 viral load (VL) was evaluated in antiretroviral therapy (ART)-naive HIV-1 infected adults.This phase IIb, observer-blind study (NCT01218113), included ART-naive HIV-1 infected adults aged 18 to 55 years. Participants were randomized to receive 2 (F4/AS01(B)_2 group, N=64) or 3 (F4/AS01(B)_3 group, N=62) doses of F4/AS01(B) or placebo (control group, N=64) at weeks 0, 4, and 28. Efficacy (HIV-1 VL, CD4(+) T-cell count, ART initiation, and HIV-related clinical events), safety, and immunogenicity (antibody and T-cell responses) were evaluated during 48 weeks.At week 48, based on a mixed model, no statistically significant difference in HIV-1 VL change from baseline was demonstrated between F4/AS01(B)_2 and control group (0.073 log(10)copies/mL [97.5% confidence interval (CI): -0.088; 0.235]), or F4/AS01(B)_3 and control group (-0.096 log(10)copies/mL [97.5% CI: -0.257; 0.065]). No differences between groups were observed in HIV-1 VL change, CD4(+) T-cell count, ART initiation, or HIV-related clinical events at intermediate timepoints. Among F4/AS01(B) recipients, the most frequent solicited symptoms were pain at injection site (252/300 doses), fatigue (137/300 doses), myalgia (105/300 doses), and headache (90/300 doses). Twelve serious adverse events were reported in 6 participants; 1 was considered vaccine-related (F4/AS01(B)_2 group: angioedema). F4/AS01(B) induced polyfunctional F4-specific CD4(+) T-cells, but had no significant impact on F4-specific CD8(+) T-cell and anti-F4 antibody levels.F4/AS01(B) had a clinically acceptable safety profile, induced F4-specific CD4(+) T-cell responses, but did not reduce HIV-1 VL, impact CD4(+) T-cells count, delay ART initiation, or prevent HIV-1 related clinical events.10 p.application/pdfengcc by (c) Dinges et al., 2016http://creativecommons.org/licenses/by/3.0/es/VIH (Virus)VacunesHIV (Viruses)Vaccinesinfo:eu-repo/semantics/article2018-07-25info:eu-repo/semantics/openAccess